ArticleBJU international2026
Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients.International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo describe the recurrence and progression trends of non-muscle-invasive bladder cancer (NMIBC) during a 14-year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5-year recurrence-free interval (RFI). PATIENTS AND
methodsWe conducted a nationwide cohort study of all patients diagnosed with NMIBC in Denmark between 2009 and 2022, linking data from population-based registries (N = 21 037). Recurrence was defined as a new bladder tumour ≥90 days after transurethral resection of bladder tumour, and progression followed the criteria set out by Lamm et al. or cystectomy. Cumulative incidence and Cox regression analyses described risks of recurrence and progression within 5 years after primary diagnosis. A landmark analysis assessed late recurrences with or without progression among patients who were recurrence-free for ≥5 years.
resultsWe identified 21 037 patients with NMIBC (median age 72 years; 76% male). The 1- and 5-year cumulative incidence of recurrence was 24% (95% confidence interval [CI] 24-25%) and 44% (95% CI 43-45%), while progression risks were 4.4% (95% CI 4.1-4.7%) and 10% (95% CI 9.7-11%). Among the 6583 patients who were recurrence-free for 5 years, the subsequent 5-year cumulative incidence was 9.8% (95% CI 9.0-11%) for recurrence and 1.5% (95% CI 1.2-1.9%) for progression, with one-third progressing to MIBC.
conclusionOur study confirmed previous findings that most recurrences in patients with NMIBC occur within the first years after primary diagnosis. Furthermore, we found improved recurrence-free rates over the past 14 years. Our analysis suggests the risk of recurrence and progression persists after a 5-year RFI; however, only in a limited proportion of patients. Future studies should identify specific risk factors able to predict patients' long-term risk, to tailor potential long-term follow-up schemes for patients with NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.